Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables - Net: 2022-2024

  • Avidity Biosciences' Receivables - Net was N/A to $1.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2023, which is 53.26% down from last year.
  • Latest data reveals that Avidity Biosciences reported Receivables - Net of $1.6 million as of Q1 2024, which was up 42.53% from $1.1 million recorded in Q4 2023.
  • Avidity Biosciences' Receivables - Net's 5-year high stood at $2.4 million during Q4 2022, with a 5-year trough of $1.1 million in Q4 2023.
  • Moreover, its 3-year median value for Receivables - Net was $1.4 million (2023), whereas its average is $1.6 million.
  • Data for Avidity Biosciences' Receivables - Net shows a maximum YoY crashed of 53.26% (in 2023) over the last 5 years.
  • Avidity Biosciences' Receivables - Net (Quarterly) stood at $2.4 million in 2022, then tumbled by 53.26% to $1.1 million in 2023, then reached $1.6 million in 2024.
  • Its Receivables - Net stands at $1.6 million for Q1 2024, versus $1.1 million for Q4 2023 and $1.2 million for Q2 2023.